Ariad (ARIA) Shares Plunge 10+% as Results of Phase 2 Study of Ponatinib Show Serious Side Effects
Go back to Ariad (ARIA) Shares Plunge 10+% as Results of Phase 2 Study of Ponatinib Show Serious Side Effects| Ariad Pharmaceuticals, Inc. (NYSE: ARIA) | Delayed: 25.17 +0.35 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.82 | 52 Week High | $14.34 | |||
| Open | $25.17 | 52 Week Low | $4.37 | |||
| Day High | $25.17 | P/E | N/A | |||
| Day Low | $25.17 | EPS | $-1.45 | |||
| Volume | 13 | |||||
